News & Updates

Treatment with either bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG + F/TDF) resulted in similarly high and sustained rates of viral suppression in adults with HIV-1* and HBV** coinfection, according to a prespecified secondary analysis of the ALLIANCE trial presented at IAS 2023.

Among treatment-naïve patients with HIV-1* infection, initial treatment combination with doravirine and islatravir (DOR/ISL) was noninferior in achieving virologic suppression (HIV-1 RNA <50 copies/mL) at week 48 compared with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), according to a trial presented at IAS 2023.

Nightly administration of atropine 0.01% eye drops does little to slow myopia progression or axial elongation in a cohort of school-aged children in the US who have low-to-moderate myopia, as shown in a study.

Misoprostol alone appears to be safe and effective for termination of first trimester pregnancy and can be used if mifepristone is unavailable or inaccessible, according to a study.

In women with heavy menstrual bleeding, treatment with levonorgestrel intrauterine system is as good as combined oral contraceptives, with both strategies improving bleeding-related quality of life, as reported in a study.

New immune-related adverse events (irAEs) start to appear more than 6 months following completion of selective immunosuppressive therapy (SIT) agents, such as infliximab and vedolizumab, for initial colitis events, reports a study.